Navigation Links
DURECT Corporation Announces Third Quarter 2013 Financial Results and Update of Programs
Date:11/4/2013

, ELADUR®, and TRANSDUR®-Sufentanil.  DURECT's proprietary oral, transdermal and injectable depot delivery technologies enable new indications and superior clinical/commercial attributes such as abuse deterrence, improved convenience, compliance, efficacy and safety for small molecule and biologic drugs.  For more information, please visit www.durect.com.

NOTE: POSIDUR™, SABER®, ORADUR®, TRANSDUR® and ELADUR® are trademarks of DURECT Corporation. Other referenced trademarks belong to their respective owners.  REMOXY, POSIDUR, ELADUR, TRANSDUR-Sufentanil, ORADUR-Methylphenidate and Relday are drug candidates under development and have not been approved for commercialization by the U.S. Food and Drug Administration or other health authorities.

DURECT Forward-Looking Statements The statements in this press release regarding the potential FDA approval or other response to our NDA for POSIDUR, additional clinical trials and potential regulatory submissions for REMOXY, the potential benefits and uses of our drug candidates, clinical trials and product development plans by our collaborators, potential collaborations with third parties and potential business development activities are forward-looking statements involving risks and uncertainties that can cause actual results to differ materially from those in such forward-looking statements. Potential risks and uncertainties include, but are not limited to, the risk of adverse decisions by regulatory agencies, including requests for additional information or product non-approval of our POSIDUR or other NDA submissions, the risk that Pfizer will discontinue development of REMOXY, delays and additional costs due to requirements imposed by regulatory agencies, potential adverse effects arising from the testing or use of our drug candidates, our potential fai
'/>"/>

SOURCE DURECT Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. DURECT Corporation Invites You to Join its Third Quarter 2013 Earnings Conference Call
2. DURECT Announces Changes to its Board of Directors
3. DURECT Corporation Announces Second Quarter 2013 Financial Results and Update of Programs
4. DURECT Corporation Announces First Quarter 2013 Financial Results and Update of Programs
5. DURECT Corporation Invites You to Join its First Quarter 2013 Earnings Conference Call
6. DURECT Corporation Invites You to Join its Fourth Quarter 2012 Earnings Conference Call
7. DURECT Corporation Announces Third Quarter 2012 Financial Results and Update of Programs
8. DURECT Corporation Invites You to Join its Third Quarter 2012 Earnings Conference Call
9. DURECT to Participate in Upcoming Healthcare Conferences
10. DURECT Corporation Announces Second Quarter 2012 Financial Results and Update of Programs
11. DURECT Corporation Announces First Quarter 2012 Financial Results and Update of Programs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... 23, 2015  A new analysis of Centers for Medicare ... data shows that 81 percent of seniors chose lower-cost ... discounts at certain pharmacies. The findings were released by ... are now the foundation of Medicare Part D," said ...
(Date:1/23/2015)... YORK , Jan. 23, 2015 /PRNewswire/-- Harwood Feffer LLP ... board of directors of Advaxis, Inc. ("Advaxis" or the ... board has breached its fiduciary duties to shareholders. ... on an investing website reporting that Advaxis had misrepresented ...
(Date:1/23/2015)... , Jan. 23, 2015  Lixte Biotechnology Holdings, Inc. (OTCQB: ... Phase I trial of Lixte,s lead compound, LB‑100, is being ... John S. Kovach , M.D., the founder and ... to be completed at a single site. Accrual of patients, ...
Breaking Medicine Technology:New Analysis: 81 Percent of Medicare Part D Seniors Choose "Preferred Pharmacy" Plans in 2015 2Harwood Feffer LLP Announces Investigation of Advaxis, Inc. 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 3
... both ethical and practical grounds, direct programming is ... pluripotent stem,cells.", WASHINGTON, Nov. 20 Two ... Cell unveil a proven way to,generate patient-matched human ... use of human embryos or human or animal ...
... of circulating cancer cells in 40,billion blood cells, ... WARREN, N.J., Nov. 20 Veridex, LLC ... (FDA) has granted an,expanded clearance for the CellSearch(TM) ... monitoring of metastatic colorectal cancer. CellSearch is currently,approved ...
Cached Medicine Technology:Two Major Studies Show: Human Pluripotent Stem Cells without Cloning or Destroying Embryo 2Two Major Studies Show: Human Pluripotent Stem Cells without Cloning or Destroying Embryo 3FDA Clears Advanced Test for Monitoring Metastatic Colorectal Cancer 2FDA Clears Advanced Test for Monitoring Metastatic Colorectal Cancer 3FDA Clears Advanced Test for Monitoring Metastatic Colorectal Cancer 4
(Date:1/22/2015)... January 22, 2015 Payday lending practices ... communities and cause financial distress to the states that ... at Howard University’s Center on Race and Wealth. , ... economic activity, payday loans at the same time substantially ...
(Date:1/22/2015)... January 22, 2015 As interest in the ... care gains momentum worldwide, Rev. Eric J. Hall , ... Network (HCCN), will be the keynote speaker on January ... Israel’s public health system. , The conference, “Hope and Resilience: ...
(Date:1/22/2015)... 2015 Compare-autoinsurance.org has released a new blog post ... auto insurance policy . , Some types of vehicles ... check the newly released blog post to see if their vehicle ... damaged vehicles are some of the cars that cannot be covered ...
(Date:1/22/2015)... Step into a macabre world where ... of Virginia. Wicked Plants, the Museum’s latest featured exhibition, ... poisonous, carnivorous and diabolical plants inside of a dilapidated, ... the biochemical, physical and neurological processes between botanicals and ...
(Date:12/26/2014)... The US represents the largest market for CRC ... forecast estimates that sales of branded therapies were $2.23 billion. ... high incidence of the disease, high drug treatment rate, and ... Increased sales of CRC therapies over the forecast period will ...
Breaking Medicine News(10 mins):Health News:Howard University Spotlights the Economic Impact of Payday Lending in Southern States 2Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 2Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 3Health News:Some Vehicles Cannot Be Covered By An Auto Insurance Policy! 2Health News:Wicked Plants are taking over the Science Museum of Virginia 2Health News:US Colorectal Cancer Drug Market Analysis and Forecast to 2023 Report Available at ReportsnReports.com 2Health News:US Colorectal Cancer Drug Market Analysis and Forecast to 2023 Report Available at ReportsnReports.com 3Health News:US Colorectal Cancer Drug Market Analysis and Forecast to 2023 Report Available at ReportsnReports.com 4
... DALLAS, Jan. 12 Affiliated Computer Services, Inc. (NYSE: ... provide Regence with Health Savings Account (HSA) administration services ... counties of Washington. Regence members will be offered the ... the addition of Regence, the largest health insurer in ...
... 12 , - Small ... , With the introduction of ... messaging device, NEC sets new standards in,mobile communications and ... innovations. , (Photo: http://www.newscom.com/cgi-bin/prnh/20090112/333834 ...
... publication of its kind aimed at healthcare fraud ... (HCI), a Verisk HealthCare company and a provider ... solutions for healthcare claims payors, announced today that ... Profiler Magazine is the nation,s ...
... Jan. 12 Wyeth Pharmaceuticals, a division of Wyeth ... announced that the companies have entered into a worldwide ... based on Santaris Pharma,s proprietary Locked Nucleic Acid (LNA) ... microRNAs (miRNAs) and messenger RNAs (mRNAs) as a means ...
... Corporation,(Nasdaq: ALUS ), the worldwide leader ... patients, today announced preliminary,unaudited record fourth quarter and ... Fourth quarter 2008 revenue improved ... of approximately $3.8 million, compared with $2.7 million ...
... to Drive Real-Time Pharmacy Utilization Management DecisionsNEWPORT ... The TriZetto Group, Inc. and Sanovia Corporation ... offer the market,s first platform that integrates ... automate prior-authorizations of medications and help plans ...
Cached Medicine News:Health News:ACS to Provide HSA Product to Regence; ACS HSA Solution Now Offered by Blue Cross Blue Shield Plans in 28 States 2Health News:NEC's new M155 Messenger Sets New Standards in Mobile Messaging 2Health News:HealthCare Insight(R) Launches Industry Fraud Magazine 2Health News:Wyeth Pharmaceuticals and Santaris Pharma Announce Strategic Alliance to Develop RNA-based Medicines 2Health News:Wyeth Pharmaceuticals and Santaris Pharma Announce Strategic Alliance to Develop RNA-based Medicines 3Health News:Wyeth Pharmaceuticals and Santaris Pharma Announce Strategic Alliance to Develop RNA-based Medicines 4Health News:Alsius Corporation Pre-Announces Record Fourth Quarter and Full Year 2008 Revenue 2Health News:Alsius Corporation Pre-Announces Record Fourth Quarter and Full Year 2008 Revenue 3Health News:TriZetto, Sanovia Join Forces to Offer First Integrated Platform That Helps Payers Control Pharmacy Costs 2Health News:TriZetto, Sanovia Join Forces to Offer First Integrated Platform That Helps Payers Control Pharmacy Costs 3
Low-profile, hand-held instrument....
Low-profile, hand-held instrument....
Developed in conjunction with Pierce E. Scranton, Jr., M.D., the Seattle Small Joint Arthroscopy Set offers meticulously designed instrumentation for elbow, foot, and ankle surgeries....
Developed in conjunction with Pierce E. Scranton, Jr., M.D., the Seattle Small Joint Arthroscopy Set offers meticulously designed instrumentation for elbow, foot, and ankle surgeries....
Medicine Products: